Atty. Docket No. PU4825USw

10/511055
DT04 Rec'd PCT/PTO 12 OCT 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Steven Gerard BLANCHARD et al.

Serial No.: To be assigned — Art Unit:

Filing Date: Concurrently herewith — Examiner:

For: *Compositions and Methods for Evaluating and Designing Nuclear Receptor Ligands that Modulate Co-regulator Affinity*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[X] Copies of the references listed on the attached form PTO-1449 as item nos. 1 and 3-48 re enclosed
[ ] Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
[X] A copy of the International Search Report which issued on International Application No. PCT/US03/11055 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as item no. 2 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

[ ] **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

B. [ ] The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[ ] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) ($180.00).

Express Mail Label No.
EV332062910US

C. [ ] The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**

[ ] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

[ ] The petition fee set forth in § 1.17(i)(1) ($180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.
[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,



Michael M. Conger
Attorney of Record:
Registration No. 43,562

Date: October 11, 2004

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-2474
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PU4825USw	SERIAL NO. To be assigned 10/961105
	APPLICANT Steven Gerard BLANCHARD et al.	
	FILING DATE Concurrently herewith	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page ___

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes | No
	1.	WO 97/31907	09/04/1997	WIPO			
	2.	WO 01/75443	10/11/2001	WIPO			

Continue on page ___

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

	3.	Bourguet et al., "Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications," *Trends in Pharmacological Sciences* **21(10)**:381-388 (Oct. 2000).
	4.	Bramlett et al., "Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes," *Molecular Endocrinology* **15(6)**:909-922 (Jun. 2001).
	5.	Brown et al., "A novel N-aryl tyrosine activator of peroxisome proliferators-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat," *Diabetes* **48(7)**:1415-1424 (Jul. 1999).
	6.	Brzozowski et al., "Molecular basis of agonism and antagonism in the oestrogen receptor," *Nature* **389(6652)**:753-758 (Oct. 1997).
	7.	Caira et al., "Cloning and characterization of RAP250, a novel nuclear receptor coactivator," *Journal of Biological Chemistry* **275(8)**:5308-5317 (Feb. 2000).
	8.	Chen et al., "A transcriptional co-repressor that interacts with nuclear hormone receptors," *Nature* **377(6548)**:454-457 (Oct. 1995).
	9.	Cobb et al., "N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent," *Journal of Medicinal Chemistry* **41(25)**:5055-5069 (Dec. 1998).
	10.	Cohen et al., "The nuclear corepressors recognize distinct nuclear receptor complexes," *Molecular Endocrinology* **14(6)**:900-914 (Jun. 2000).
	11.	Collins et al., "N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," *Journal of Medicinal Chemistry* **41(25)**:5037-5054 (Dec. 1998).
	12.	Darimont et al., "Structure and specificity of nuclear receptor-coactivator interactions," *Genes & Development* **12(21)**:3343-3356 (Nov. 1998).
	13.	DiRenzo et al., "Peroxisome proliferators-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors," *Molecular & Cellular Biology* **17(4)**:2166-2176 (Apr. 1997).

Continue on page 2

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Express Mail Label No.
EV332062910US

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PU4825USw	SERIAL NO. To be assigned 10/511055
	APPLICANT Steven Gerard BLANCHARD et al.	
	FILING DATE Concurrently herewith	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page ____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes | No

Continue on page ____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) (Cont'd)

	14.	Dowell et al., "p300 functions as a coactivator for the peroxisome proliferators-activated receptor alpha," *Journal of Biological Chemistry* **272(52)**:33435-33443 (Dec. 1997).
	15.	Gampe et al., "Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors," *Molecular Cell* **5(3)**:545-555 (Mar. 2000).
	16.	Gee et al., "Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor," *Molecular Endocrinology* **13(11)**:1912-1923 (Nov. 1999).
	17.	Grignani et al., "Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia," *Nature* **391(6669)**:815-818 (Feb. 1998).
	18.	Henke et al., "N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents,' *Journal of Medicinal Chemistry* **41(25)**:5020-5036 (Dec. 1998).
	19.	Horlein et al., "Ligand-independent repression by the thyroid hormone receptor mediated by anuclear receptor co-repressor," *Nature* **377(6548)**:397-404 (Oct. 1995).
	20.	Hu et al., "The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors," *Nature* **402(6757)**:93-96 (Nov. 1999).
	21.	Issemann et al., "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators," *Nature* **347(6294)**:645-650 (Oct. 1990).
	22.	Kliewer et al., "Differential expression and activation of a family of murine peroxisome proliferators-activated receptors," *Proc. Nat'l. Acad. Sci. USA* **91(15)**:7355-7359 (Jul. 1994).
	23.	Lavinsky et al., "Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes *Proc. Nat'l. Acad. Sci. USA* **95(6)**:2920-2925 (Mar. 1998).
	24.	Lee et al., "A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors *in vivo*," *Journal of Biological Chemistry* **274(48)**:34283-34293 (Nov. 1999).

Continue on page _3__

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PU4825USw	SERIAL NO. To be assigned 10/511055
	APPLICANT Steven Gerard BLANCHARD et al.	
	FILING DATE Concurrently herewith	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page ____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes | No

Continue on page ____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) (Cont'd)

	25.	Lehmann et al., "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators-activated receptor gamma (PPAR gamma)," *Journal of Biological Chemistry* **270(22)**:12953-12956 (Jun. 1995).
	26.	Nagy et al., "Mechanism of corepressor binding and release from nuclear hormone receptors," *Genes & Development* **13(24)**:3209-3216 (Dec. 1999).
	27.	Nolte et al., "Ligand binding and co-activator assembly of the peroxisome proliferators-activated receptor-gamma," *Nature* **395(6698)**:137-143 (Sep. 1998).
	28.	Norris et al., "Peptide antagonists of the human estrogen receptor," *Science* **285(5428)**:744-746 (Jul. 1999).
	29.	Oliver et al., "A selective peroxisome proliferators-activated receptor delta agonist promotes reverse cholesterol transport," *Proc. Nat'l. Acad. Sci. USA* **98(9)**:5306-5311 (Apr. 2001).
	30.	Perissi et al., "Molecular determinants of nuclear receptor-corepressor interaction," *Genes & Development* **13(24)**:3198-3208 (Dec. 1999).
	31.	Pike et al., "Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist," *EMBO Journal* **18(17)**:4608-4618 (Sep. 1999).:
	32.	Puigserver et al., "A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis," *Cell* **92(6)**:829-839 (Mar. 1998).
	33.	Robyr et al., "Nuclear hormone receptor coregulators in action: diversity for shared tasks," *Molecular Endocrinology* **14(3)**:329-347 (Mar. 2000).
	34.	Shiau et al., "The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen," *Cell* **95(7)**:927-937 (Dec. 1998.)
	35.	Warnmark et al., "Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERalpha and ERbeta," *J. Biol. Chem.* **276(26)**:23397-23404 (Jun. 2001).
	36.	Webb et al., "The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs)," *Molecular Endocrinology* **14(12)**:1976-1985 (Dec. 2000).

Continue on page 4

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PU4825USw	SERIAL NO. To be assigned 10/511055
	APPLICANT Steven Gerard BLANCHARD et al.	
	FILING DATE Concurrently herewith	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page ___

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes | No

Continue on page ___

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) (Cont'd)

	37.	Willson et al., "The PPARs: from orphan receptors to drug discovery," *Journal of Medicinal Chemistry* **43(4)**:527-550 (Feb. 2000).
	38.	Wong et al., "Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands," *Biochemistry* **40(23)**:6756-6765 (Jun. 2001).
	39.	Xu et al., "Molecular recognition of fatty acids by peroxisome proliferators-activated receptors," *Molecular Cell* **3(3)**:397-403 (Mar. 1999).
	40.	Xu et al., "Structural determinants of ligand binding selectivity between the peroxisome proliferators-activated receptors, " *Proc. Nat'l. Acad. Sci. USA* **98(24)**:13919-13924 (Nov. 2001).
	41.	Xu et al., "Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα," *Nature* **415(6873)**:813-817 (Feb. 2002).
	42.	Yamamoto et al., "The Tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced Tamoxifen-dependent interaction with corepressor complexes," *Journal of Biological Chemistry* **276(46)**:42684-42691 (Nov. 2001).
	43.	Yoh et al., "Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors," *Molecular Endocrinology* **11(4)**:470-480 (Apr. 1997).
	44.	Yuan et al., "The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion," *Proc. Nat'l Acad. Of Sci. USA* **95(14)**:7939-7944 (Jul. 1998).
	45.	Zhang et al., "A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor," *Molecular Endocrinology* **12(4)**:513-524 (Apr. 1998).
	46.	Zhu et al., "Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferators-activated receptor gamma," *Gene Expression* **6(3)**:185-195 (1996).
	47.	Zhu et al., "Isolation and characterization of PBP, a protein that interacts with peroxisome proliferators-activated receptor," *Journal of Biological Chemistry* **272(41)**:25500-25506 (Oct. 1997).
	48.	Zhu et al., "Isolation and characterization of peroxisome proliferators-activated receptor (PPAR interacting protein (PRIP) as a coactivator for PPAR," *Journal of Biological Chemistry* **275(18)**:13510-13516 (May 2000).

Continue on page ___

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.